- Home
- PTA vs ARQT Comparison
PTA vs ARQT Comparison
Compare PTA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PTA | ARQT |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 3.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PTA | ARQT |
|---|---|---|
| Price | $19.54 | $23.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.86 |
| AVG Volume (30 Days) | 133.1K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 8.31% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.46 |
| Revenue Next Year | N/A | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $17.40 | $11.86 |
| 52 Week High | $20.92 | $31.77 |
Technical Indicators
Market Signals| Indicator | PTA | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 39.13 | 39.11 |
| Support Level | $19.40 | $22.26 |
| Resistance Level | $19.60 | $27.65 |
| Average True Range (ATR) | 0.14 | 1.59 |
| MACD | -0.03 | -0.31 |
| Stochastic Oscillator | 0.00 | 16.47 |
Price Performance
Historical ComparisonAbout PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.